Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
The review found no eligible studies for this question.
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
Nasal intermittent positive pressure ventilation (NIPPV) probably leads to lower respiratory failure compared with nasal continuous positive airway pressure (NCPAP) (by population) (moderate certainty).
Nasal intermittent positive pressure ventilation (NIPPV) probably leads to lower need for endotracheal tube ventilation compared with nasal continuous positive airway pressure (NCPAP) (by population) (moderate certainty).
Nasal intermittent positive pressure ventilation (NIPPV) showed no clear difference in mortality during study period compared with nasal continuous positive airway pressure (NCPAP) (by population) (low certainty).
Nasal intermittent positive pressure ventilation (NIPPV) may leads to lower chronic lung disease compared with nasal continuous positive airway pressure (NCPAP) (by population) (low certainty).
Nasal intermittent positive pressure ventilation (NIPPV) showed no clear difference in pneumothorax compared with nasal continuous positive airway pressure (NCPAP) (by population) (low certainty).
Nasal intermittent positive pressure ventilation (NIPPV) showed no clear difference in severe intraventricular hemorrhage (grade III/IV) compared with nasal continuous positive airway pressure (NCPAP) (by population) (low certainty).
Systemic aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Topical aminocaproic acid showed no clear difference in secondary hemorrhage at any time point compared with placebo (low certainty).
The review found no eligible studies for this question.
Systemic tranexamic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with control (moderate certainty).
The review found no eligible studies for this question.